Xing Liu

Xing Liu

Auto-generated profile, based on publicly available information

Xing Liu

Department of Thyroid and Neck Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YHYan He
Yan He
XLXing Liu
Xing Liu
MWMin Wang
Min Wang
HKHonghong Ke
Honghong Ke
CGChenliang Ge
Chenliang Ge
This study aims to evaluate the neutrophil-to-lymphocyte ratio (NLR) as a predictive biomarker for cardiovascular mortality among cancer patients, utilizing data from the National Health and Nutrition Examination Survey (NHANES). From the NHANES dataset (2007–2018), we analyzed 4974 cancer survivors, investigating the prognostic significance of NLR for all-cause, cardiovascular, and cancer-specific mortality. Survival outcomes were analyzed using Cox regression and Kaplan–Meier methods. Optimal NLR cutoffs were identified as 2.61 for differentiating the higher NLR group from lower NLR group. Elevated NLR levels significantly correlated with increased all-cause mortality (HR 1.11, 95% CI 1.07–1.14, P < 0.001) and cardiovascular mortality (HR 1.14, 95% CI 1.08–1.21, P < 0.001) in adjusted models. Subgroup analyses revealed that age, sex, smoking status, and hypertension significantly influence NLR’s association with cardiovascular mortality. Specific cancers including breast, prostate, non-melanoma skin, colon and melanoma experience increased all-cause and cardiovascular mortality in the higher NLR group compared to lower NLR group. Elevated NLR is a significant predictor of increased mortality in cancer patients, particularly for cardiovascular outcomes. These findings support that NLR acts as a pivotal prognostic tool with significant implications for clinical practice in the realm of cardio-oncology.

20 November 2024 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
XLXing Liu
Xing Liu
WYWenjing Yang
Wenjing Yang
TZTeng Zhao
Teng Zhao
QWQian Wang
Qian Wang
JWJiacheng Wang
Jiacheng Wang
BWBojun Wei
Bojun Wei